HeartSciences Inc. (HSCSW) company profile
Close on Oct 30, 2026Market cap $15.89MP/E –Yield 0.00%
About HeartSciences
Finance Services, SIC 6199
HeartSciences is a medical technology company that develops artificial intelligence-driven electrocardiography solutions to enhance cardiac care. Its flagship product is MyoVista Insights, a cloud-based, device-agnostic ECG data management platform designed to organize clinical workflows and integrate multi-vendor AI-ECG algorithms. The company also develops the MyoVista wavECG device, a point-of-care resting twelve-lead ECG system engineered to host embedded cardiac analysis algorithms. HeartSciences serves healthcare providers ranging from primary care settings to large hospital systems and cardiology practices seeking modernized ECG infrastructure and risk assessment tools.
The company operates primarily in the United States and maintains international intellectual property protections across jurisdictions including Europe, Canada, Japan, India, and China. HeartSciences employs a five-person research and development staff to advance its proprietary software and device capabilities. The company’s headquarters are not stated in the provided text.
Summary of the business section of HeartSciences's latest annual report, written by StockData.
Company profile
Company
- Legal name
- HeartSciences Inc.
- Founded
- 2007
- Headquarters
- Southlake, TX
- Address
- 550 Reserve St, Suite 360 76092
- Phone
- (682) 237-7781
- Website
- heartsciences.com
- Industry
- Finance Services
- Incorporated in
- Texas
- Fiscal year ends
- April 30
- Auditor
- HASKELL & WHITE LLP, Irvine, California
Stock & identifiers
- Ticker
- HSCSW
- Other tickers
- HSCS
- Exchange
- Nasdaq
- IPO date
- Jun 17, 2022
- Shares outstanding
- 5M, Sep 11, 2026
- Public float
- $10.40M, Sep 30, 2023
- Filer category
- <br>Emerging growth company
- Stock splits
- 1-for-100 reverse, May 17, 2024
- SEC CIK
- 1468492
- CUSIP
- 42254E112
- ISIN
- US42254E1120
- FIGI
- BBG0185L9036
- LEI
- 254900TRRGAWZYCX1Q54
- EIN
- 26-1344466
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Andrew Simpson | See Remarks, Director | 499,382 |
| Danielle Watson | See Remarks | – |
| Mark T. Hilz | See Remarks | 4,793 |
| David R. Wells | Director | – |
| Bruce Bent | Director | 1,638 |
| Brian Szymczak | Director | 6,060 |
Executive compensation, fiscal 2025
Summary compensation table from the latest proxy statement
| Executive | Salary | Bonus | Option awards | Total | vs. prior year |
|---|---|---|---|---|---|
| Andrew Simpson President, Chief Executive Officer and Chairman of the Board of Directors | $345.83K | $65.00K | $116.34K | $527.17K | +76% |
| Mark Hilz Chief Operating Officer and Secretary | $337.88K | $65.00K | $116.34K | $519.22K | +73% |
| Danielle Watson Chief Financial Officer and Treasurer | $203.67K | $30.00K | $23.27K | $256.94K | +43% |
Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.
IPO
From the final prospectus (Form 424B4) and the first day of trading
Offering
- Type
- Initial public offering
- Final prospectus filed
- Jun 17, 2022
- Offer price
- $4.25
- Securities offered
- 1,500,000
- Gross proceeds
- $6.38M
- Exchange
- Nasdaq
- First trading day
- Jun 15, 2022
- First-day close
- $1.70-60.0%
- Lock-up ends (est.)
- Dec 12, 2022
“The initial public offering price is $4.25 per Unit.”
Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.
Corporate history
Events identified from SEC filings